MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Ramiro Guerrero Purchases 8,931 Shares

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ramiro Guerrero bought 8,931 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The stock was acquired at an average cost of $1.39 per share, for a total transaction of $12,414.09. Following the completion of the purchase, the director directly owned 610,842 shares of the company’s stock, valued at $849,070.38. The trade was a 1.48% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Ramiro Guerrero also recently made the following trade(s):

• On Friday, August 28th, Ramiro Guerrero purchased 46,620 shares of MAIA Biotechnology stock. The shares were acquired at an average cost of $1.35 per share, with a total value of $62,937.00.
• On Thursday, August 27th, Ramiro Guerrero acquired 78,239 shares of MAIA Biotechnology stock. The stock was acquired at an average price of $1.39 per share, for a total transaction of $108,752.21.
• On Monday, August 24th, Ramiro Guerrero bought 1,794 shares of MAIA Biotechnology stock. The shares were acquired at an average price of $1.33 per share, with a total value of $2,386.02.
• On Thursday, August 20th, Ramiro Guerrero purchased 11,899 shares of MAIA Biotechnology stock. The stock was acquired at an average cost of $1.37 per share, with a total value of $16,301.63.

MAIA Biotechnology Trading Down 0.8%

Shares of MAIA Biotechnology stock opened at $1.30 on Wednesday. MAIA Biotechnology, Inc. has a 12-month low of $0.87 and a 12-month high of $3.19. The company has a market cap of $79.08 million, a P/E ratio of -2.10 and a beta of 0.25. The company’s fifty day simple moving average is $1.37 and its two-hundred day simple moving average is $1.43.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its earnings results on Monday, August 10th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Analysts predict that MAIA Biotechnology, Inc. will post -0.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in MAIA. Susquehanna International Group LLP bought a new position in shares of MAIA Biotechnology in the 2nd quarter worth approximately $51,000. Cable Car Capital LP bought a new stake in shares of MAIA Biotechnology during the second quarter valued at approximately $741,000. Solas Capital Management LLC purchased a new stake in MAIA Biotechnology in the second quarter worth $4,364,000. BlackRock Inc. purchased a new stake in MAIA Biotechnology in the second quarter worth $580,000. Finally, Centric Wealth Management bought a new position in MAIA Biotechnology in the second quarter worth $1,107,000. Hedge funds and other institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.